Abstract
Statins are the primary pharmacological intervention to reduce LDL cholesterol; they significantly reduce inflammatory markers. Ezetimibe also reduces LDL cholesterol and reduces cardiovascular events when given on top of statin therapy. Whether ezetimibe, like statins, reduces markers of inflammation is less clear. We, therefore, conducted a systematic literature research addressing the impact of ezetimibe on CRP, TNFα and IL-6 when given on top of statin therapy. Our work indicates that overall ezetimibe reduces inflammation on top of statin treatment. However, available data are limited for CRP and even more so for TNFα and IL-6.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data availability
Enquiries about data availability should be directed to the authors.
References
Almquist T, Jacobson SH, Mobarrez F et al (2014) Lipid-lowering treatment and inflammatory mediators in diabetes and chronic kidney disease. Eur J Clin Invest 44:276–284. https://doi.org/10.1111/eci.12230
Azar M, Valentin E, Badaoui G et al (2011) Comparison of the effects of combination atorvastatin (40 mg) + ezetimibe (10 mg) versus atorvastatin (40 mg) alone on secretory phospholipase A2 activity in patients with stable coronary artery disease or coronary artery disease equivalent. Am J Cardiol 107:1571–1574. https://doi.org/10.1016/j.amjcard.2011.01.038
Ballantyne CM, Houri J, Notarbartolo A et al (2003) Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation 107:2409–2415. https://doi.org/10.1161/01.CIR.0000068312.21969.C8
Ballantyne CM, Weiss R, Moccetti T et al (2007) Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study). Am J Cardiol 99:673–680. https://doi.org/10.1016/j.amjcard.2006.10.022
Barbosa SP, Lins LC, Fonseca FA et al (2013) Effects of ezetimibe on markers of synthesis and absorption of cholesterol in high-risk patients with elevated C-reactive protein. Life Sci 92:845–851. https://doi.org/10.1016/j.lfs.2013.02.018
Bays HE, Ose L, Fraser N et al (2004) A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary. Clin Ther 26:1758–1773. https://doi.org/10.1016/j.clinthera.2004.11.016
Berthold HK, Berneis K, Mantzoros CS et al (2013) Effects of simvastatin and ezetimibe on interleukin-6 and high-sensitivity C-reactive protein. Scand Cardiovasc J 47:20–27. https://doi.org/10.3109/14017431.2012.734635
Bohula EA, Giugliano RP, Cannon CP et al (2015) Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT. Circulation 132:1224–1233. https://doi.org/10.1161/CIRCULATIONAHA.115.018381
Collins R, Armitage J, Parish S et al (2002) MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360:7–22. https://doi.org/10.1016/S0140-6736(02)09327-3
Dawson JA, Choke E, Loftus IM et al (2011) A randomised placebo-controlled double-blind trial to evaluate lipid-lowering pharmacotherapy on proteolysis and inflammation in abdominal aortic aneurysms. Eur J Vasc Endovasc Surg 41:28–35. https://doi.org/10.1016/j.ejvs.2010.08.023
Dolezelova E, Stein E, Derosa G et al (2017) Effect of ezetimibe on plasma adipokines: a systematic review and meta-analysis. Br J Clin Pharmacol 83:1380–1396. https://doi.org/10.1111/bcp.13250
Feldman T, Davidson M, Shah A et al (2006) Comparison of the lipid-modifying efficacy and safety profiles of ezetimibe coadministered with simvastatin in older versus younger patients with primary hypercholesterolemia: a post Hoc analysis of subpopulations from three pooled clinical trials. Clin Ther 28:849–859. https://doi.org/10.1016/j.clinthera.2006.06.001
Ference BA, Ginsberg HN, Graham I et al (2017) Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. a consensus statement from the European atherosclerosis society consensus panel. Eur Heart J 38:2459–2472. https://doi.org/10.1093/EURHEARTJ/EHX144
Habara M, Nasu K, Terashima M et al (2014) Impact on optical coherence tomographic coronary findings of fluvastatin alone versus fluvastatin + ezetimibe. Am J Cardiol 113:580–587. https://doi.org/10.1016/j.amjcard.2013.10.038
Krysiak R, Zmuda W, Okopien B (2014) The effect of simvastatin-ezetimibe combination therapy on adipose tissue hormones and systemic inflammation in patients with isolated hypercholesterolemia. Cardiovasc Ther 32:40–46. https://doi.org/10.1111/1755-5922.12057
Krysiak R, Okopień B (2011) The effect of ezetimibe and simvastatin on monocyte cytokine release in patients with isolated hypercholesterolemia. J Cardiovasc Pharmaco. https://doi.org/10.1097/FJC.0b013e318211703b
Lins LCA, França CN, Fonseca FAH et al (2014) Effects of ezetimibe on endothelial progenitor cells and microparticles in high-risk patients. Cell Biochem Biophys 70:687–696. https://doi.org/10.1007/s12013-014-9973-9
Oh M, Kim H, Shin EW et al (2021) Statin/ezetimibe combination therapy vs statin monotherapy for carotid atherosclerotic plaque inflammation. Medicine (baltimore) 100:e25114. https://doi.org/10.1097/MD.0000000000025114
Mach F, Baigent C, Catapano AL et al (2020) 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 41:111–188. https://doi.org/10.1093/EURHEARTJ/EHZ455
Marcus ME, Manne-Goehler J, Theilmann M et al (2022) Use of statins for the prevention of cardiovascular disease in 41 low-income and middle-income countries: a cross-sectional study of nationally representative, individual-level data. Lancet Glob Heal 10:e369–e379. https://doi.org/10.1016/S2214-109X(21)00551-9/ATTACHMENT/7B1276F1-8390-4F14-ABBC-DF73DC627832/MMC2.PDF
Morrone D, Weintraub WS, Toth PP et al (2012) Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials. Atherosclerosis 223:251–261. https://doi.org/10.1016/j.atherosclerosis.2012.02.016
Newman CB, Tobert JA (2015) Statin intolerance: reconciling clinical trials and clinical experience. JAMA–J Am Med Assoc 313:1011–1012. https://doi.org/10.1001/jama.2015.1335
Nicholls SJ, Ray KK, Ballantyne CM et al (2017) Comparative effects of cholesteryl ester transfer protein inhibition, statin or ezetimibe on lipid factors: the accentuate trial. Atherosclerosis 261:12–18. https://doi.org/10.1016/j.atherosclerosis.2017.04.008
Oh MS, Min YJ, Kwon JE et al (2011) Effects of ezetimibe added to ongoing statin therapy on C-reactive protein levels in hypercholesterolemic patients. Korean Circ J 41:253–258. https://doi.org/10.4070/kcj.2011.41.5.253
Padhy BM, Yadav R, Gupta YK (2013) Hypolipidaemic and anti-inflammatory effects of fixed dose combination of atorvastatin plus ezetimibe in Indian patients with dyslipidaemia. Singapore Med J 54:90–95. https://doi.org/10.11622/smedj.2013031
Pearson T, Ballantyne C, Sisk C et al (2007) Comparison of effects of ezetimibe/simvastatin versus simvastatin versus atorvastatin in reducing C-reactive protein and low-density lipoprotein cholesterol levels. Am J Cardiol 99:1706-1713.e1. https://doi.org/10.1016/j.amjcard.2007.01.062
Prati F, Marco V, Paoletti G, Albertucci M (2020) Coronary inflammation: why searching, how to identify and treat it. Eur Hear J Suppl 22:E121–E124. https://doi.org/10.1093/EURHEARTJ/SUAA076
Ren Y, Zhu H, Fan Z et al (2017) Comparison of the effect of rosuvastatin versus rosuvastatin/ezetimibe on markers of inflammation in patients with acute myocardial infarction. Exp Ther Med 14:4942. https://doi.org/10.3892/ETM.2017.5175
Ridker PM, Cannon CP, Morrow D et al (2005) C-Reactive protein levels and outcomes after statin therapy. N Engl J Med 352:20–28. https://doi.org/10.1056/NEJMoa042378
Ridker PM, Danielson E, Fonseca FAH et al (2008) Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359:2195–2207. https://doi.org/10.1056/NEJMoa0807646
Sager PT, Melani L, Lipka L et al (2003) Effect of coadministration of ezetimibe and simvastatin on high-sensitivity C-reactive protein. Am J Cardiol 92:1414–1418. https://doi.org/10.1016/j.amjcard.2003.08.048
Sager PT, Capece R, Lipka L et al (2005) Effects of ezetimibe coadministered with simvastatin on C-reactive protein in a large cohort of hypercholesterolemic patients. Atherosclerosis 179:361–367. https://doi.org/10.1016/j.atherosclerosis.2004.10.021
Sahebkar A, Di Giosia P, Stamerra CA et al (2016) Effect of monoclonal antibodies to PCSK9 on high-sensitivity C-reactive protein levels: a meta-analysis of 16 randomized controlled treatment arms. Br J Clin Pharmacol 81:1175–1190. https://doi.org/10.1111/bcp.12905
Salgado MM, Manchado A, Nieto CT et al (2021) Synthesis and modeling of ezetimibe analogues. Molecules. https://doi.org/10.3390/molecules26113107
Samuel M, Tardif JC, Khairy P et al (2021) Cost-effectiveness of low-dose colchicine after myocardial infarction in the colchicine cardiovascular outcomes trial (COLCOT). Eur Hear J Qual Care Clin Outcomes 7:486. https://doi.org/10.1093/EHJQCCO/QCAA045
Shepherd J, Cobbe SM, Ford I et al (1995) Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 333:1301–1308. https://doi.org/10.1056/NEJM199511163332001
Sirtori CR (2014) The pharmacology of statins. Pharmacol Res 88:3–11. https://doi.org/10.1016/j.phrs.2014.03.002
Study P, Alvarez-sala LA, Cachofeiro V et al (2008) Effects of fluvastatin extended-release (80 mg ) alone and in combination with ezetimibe (10 mg ) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia : a 12-week. Lipids. https://doi.org/10.1016/j.clinthera.2008.01.013
Undas A, MacHnik A, Potaczek DP et al (2011) Ezetimibe combined with simvastatin compared with simvastatin alone results in a greater suppression of oxidative stress and enhanced fibrinolysis in patients after acute coronary events. J Cardiovasc Pharmacol 58:167–172. https://doi.org/10.1097/FJC.0b013e31821e8cb2
Wang X, Zhao X, Li L et al (2016) Effects of combination of ezetimibe and rosuvastatin on coronary artery plaque in patients with coronary heart disease. Hear Lung Circ 25:459–465. https://doi.org/10.1016/j.hlc.2015.10.012
Wang J, Ai XB, Wang F et al (2017) Efficacy of ezetimibe combined with atorvastatin in the treatment of carotid artery plaque in patients with type 2 diabetes mellitus complicated with coronary heart disease. Int Angiol 36:467–473. https://doi.org/10.23736/S0392-9590.17.03818-4
Yu E, Malik VS, Hu FB (2018) Cardiovascular disease prevention by diet modification: JACC health promotion series HHS public access. J Am Coll Cardiol 72:914–926. https://doi.org/10.1016/j.jacc.2018.02.085
Zhao TX, Kostapanol M, Griffiths C et al (2018) Low dose interleukin-2 in patients with stable ischaemic heart disease and acute coronary syndrome (LILACS). https://doi.org/10.1136/bmjopen-2018-022452
Funding
This research and the authors did not receive any funding.
Author information
Authors and Affiliations
Contributions
MK: conceived and designed the analysis; collected the data; contributed data; performed the analysis; wrote the paper. HD: conceived and designed the analysis; review and editing. CHS: conceived and designed the analysis; collected the data; contributed data; performed the analysis; review and editing.
Corresponding author
Ethics declarations
Conflict of interest
Margaretha Klement: None. Heinz Drexel: Consultant and speaker fees from MSD, Amgen, Sanofi-Aventis, and Astra Zeneca. Christoph H. Saely: Consultant and speaker fees from MSD, Amgen, Sanofi-Aventis, and Astra Zeneca.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Margaretha Klement takes responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Klement, M., Drexel, H. & Saely, C.H. Impact of ezetimibe on markers of inflammation in patients treated with statins: a systematic review. Inflammopharmacol 31, 1647–1656 (2023). https://doi.org/10.1007/s10787-023-01209-w
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10787-023-01209-w